clinical trial · NCT06683742
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals, Inc.·phase3·active not recruiting·n = 400
Wet Age Related Macular DegenerationwAMDEYP-1901Aflibercept (2.0 mg)
brief summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
started
Nov 27, 2024
primary completion
Oct 1, 2026
completion
Oct 1, 2027
last updated
Jul 6, 2026
official title
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol